GSBS Student Publications
GSBS Program
Cancer Biology
UMMS Affiliation
Department of Biochemistry and Molecular Pharmacology
Date
1-1-2013
Document Type
Article
Disciplines
Cancer Biology | Neoplasms | Therapeutics
Abstract
Glioblastoma multiforme (GBM) is a grade IV brain tumor characterized by a heterogeneous population of cells that are highly infiltrative, angiogenic and resistant to chemotherapy. The current standard of care, comprised of surgical resection followed by radiation and the chemotherapeutic agent temozolomide, only provides patients with a 12-14 month survival period post-diagnosis. Long-term survival for GBM patients remains uncommon as cells with intrinsic or acquired resistance to treatment repopulate the tumor. In this review we will describe the mechanisms of resistance, and how they may be overcome to improve the survival of GBM patients by implementing novel chemotherapy drugs, new drug combinations and new approaches relating to DNA damage, angiogenesis and autophagy.
Rights and Permissions
Citation: Ramirez YP, Weatherbee JL, Wheelhouse RT, Ross AH. Glioblastoma multiforme therapy and mechanisms of resistance. Pharmaceuticals (Basel). 2013 Nov 25;6(12):1475-506. doi: 10.3390/ph6121475. Link to article on publisher's website
DOI of Published Version
10.3390/ph6121475
Related Resources
Keywords
angiogenesis, autophagy, imidazotetrazine, MGMT, DNA repair, temozolomide, cancer stem cells
Journal Title
Pharmaceuticals (Basel)
PubMed ID
24287492
Creative Commons License
This work is licensed under a Creative Commons Attribution 3.0 License.
Repository Citation
Ramirez, Yulian; Weatherbee, Jessica L.; Wheelhouse, Richard T.; and Ross, Alonzo H., "Glioblastoma multiforme therapy and mechanisms of resistance" (2013). GSBS Student Publications. 1869.
https://escholarship.umassmed.edu/gsbs_sp/1869
Included in
Cancer Biology Commons, Neoplasms Commons, Therapeutics Commons